Link Pharma Chem Ltd Valuation Shifts to Very Attractive Amid Mixed Market Performance

Valuation Metrics Signal Improved Price Attractiveness

Link Pharma Chem’s current P/E ratio stands at a high 95.0, which on the surface may appear expensive. However, this figure must be contextualised within the company’s recent earnings volatility and sector dynamics. More importantly, the price-to-book value ratio has compressed to 1.02, indicating that the stock is trading close to its book value, a level often considered attractive for commodity chemical firms given their asset-heavy nature.

The enterprise value to EBITDA (EV/EBITDA) multiple is 13.68, which is significantly lower than several peers in the industry. For instance, Stallion India and Sanstar Chemicals trade at EV/EBITDA multiples of 36.41 and 85.40 respectively, underscoring Link Pharma Chem’s relative valuation appeal. This compression in valuation multiples has driven the MarketsMOJO valuation grade upgrade from “risky” to “very attractive” as of 19 May 2025.

Additionally, the PEG ratio of 0.71 suggests that the stock is undervalued relative to its expected earnings growth, a positive sign for investors seeking growth at a reasonable price. This contrasts with peers such as Titan Biotech, which has a PEG ratio of 1.89, indicating a pricier growth premium.

Comparative Analysis with Industry Peers

When benchmarked against its commodity chemicals sector peers, Link Pharma Chem’s valuation stands out for its relative affordability. While companies like Sanstar and Stallion India are classified as “Very Expensive” with P/E ratios of 84.2 and 56.28 respectively, Link Pharma Chem’s valuation grade improvement reflects a more compelling risk-reward profile.

Other peers such as Gulshan Polyols and Oriental Aromatics are also rated “Very Attractive,” but their P/E ratios vary widely, with Oriental Aromatics showing an exceptionally high P/E of 1283.16, likely due to earnings anomalies or one-off factors. Link Pharma Chem’s more moderate multiples, combined with an EV to capital employed ratio of 1.01 and EV to sales of 0.73, suggest efficient capital utilisation and reasonable sales valuation.

However, it is important to note that the company’s return on capital employed (ROCE) remains negative at -0.51%, and return on equity (ROE) is modest at 1.07%. These figures highlight ongoing operational challenges that investors should monitor closely despite the attractive valuation.

Stock Price and Market Performance Overview

Link Pharma Chem’s stock price closed at ₹29.95 on 17 Feb 2026, marginally down 0.13% from the previous close of ₹29.99. The stock has traded within a 52-week range of ₹26.40 to ₹42.80, indicating some volatility but also a potential floor near current levels. The intraday range on the latest trading day was narrow, between ₹29.95 and ₹29.99, reflecting subdued price movement.

In terms of returns, the stock has outperformed the Sensex over shorter periods but lagged over longer horizons. For example, over the past week and month, Link Pharma Chem delivered positive returns of 3.28% and 6.66% respectively, while the Sensex declined by 0.94% and 0.35%. Year-to-date, the stock is down 2.76%, slightly worse than the Sensex’s 2.28% decline.

Longer-term performance reveals challenges: over one year, the stock has fallen 17.95% compared to the Sensex’s 9.66% gain, and over three years, it has declined 34.61% while the Sensex rose 35.81%. However, over five and ten years, Link Pharma Chem has delivered cumulative returns of 13.88% and 125.19% respectively, demonstrating resilience over extended periods despite recent headwinds.

Mojo Score and Rating Update

MarketsMOJO assigns Link Pharma Chem a Mojo Score of 32.0, reflecting a cautious stance on the stock’s overall quality and outlook. The Mojo Grade was upgraded from “Strong Sell” to “Sell” on 19 May 2025, signalling a slight improvement in fundamentals or valuation but still indicating a below-average investment proposition.

The company’s market capitalisation grade is rated 4, suggesting a mid-tier market cap within its sector. This rating, combined with the valuation upgrade, may attract value investors seeking turnaround opportunities, though the low ROCE and ROE metrics warrant careful scrutiny.

Investment Considerations and Outlook

Link Pharma Chem’s shift to a “very attractive” valuation grade is primarily driven by compressed price multiples and a PEG ratio below 1, signalling potential undervaluation relative to growth prospects. This repositioning contrasts with many peers in the commodity chemicals sector, which remain expensive or very expensive by traditional valuation metrics.

Nevertheless, investors should weigh these valuation benefits against operational challenges, including negative ROCE and modest ROE, which may constrain near-term profitability and cash flow generation. The stock’s recent underperformance relative to the Sensex over one and three years also highlights risks associated with cyclical pressures and sector-specific headwinds.

For those considering exposure to commodity chemicals, Link Pharma Chem offers an intriguing risk-reward profile, particularly for investors with a longer-term horizon willing to tolerate volatility. The valuation reset may provide a margin of safety, but ongoing monitoring of earnings recovery and capital efficiency will be critical.

Conclusion

Link Pharma Chem Ltd’s recent valuation upgrade to “very attractive” reflects a significant shift in market perception, driven by compressed P/E and P/BV ratios relative to peers and historical levels. While the company faces operational challenges as evidenced by negative ROCE and subdued ROE, the current price multiples and PEG ratio suggest a potential entry point for value investors.

However, the stock’s mixed performance against the broader market and sector peers underscores the need for cautious optimism. Investors should balance the appeal of valuation against fundamental risks and monitor quarterly earnings and capital efficiency metrics closely. As always, diversification and alignment with individual risk tolerance remain paramount when considering exposure to commodity chemical stocks like Link Pharma Chem.

Unlock special upgrade rates for a limited period. Start Saving Now →